Tags

Type your tag names separated by a space and hit enter

Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial.

Abstract

Animal studies have shown that soy isoflavones have an effect in preventing estrogen-related bone loss, but few data are available in humans, especially in the Asian populations. This double-blind, placebo-controlled, randomized trial examines the effects of soy isoflavones on bone loss in postmenopausal Chinese women, aged 48-62 yr. Two hundred and three eligible subjects were randomly assigned to three treatment groups with daily doses of placebo (1 g starch; n = 67), mid-dose (0.5 g starch, 0.5 g soy extracts, and approximately 40 mg isoflavones; n = 68), and high dose (1.0 g soy extracts and approximately 80 mg isoflavones; n = 68). All were given 12.5 mmol (500 mg) calcium and 125 IU vitamin D(3). Bone mineral density (BMD) and bone mineral content (BMC) of the whole body, spine, and hip were measured using dual energy x-ray absorptiometry at baseline and 1 yr post treatment. Both univariate and multivariate analyses showed that women in the high dose group had mild, but statistically significantly, higher favorable change rate in BMC at the total hip and trochanter (P < 0.05) compared with the placebo and mid-dose groups, even after further adjustments for the potential confounding factors. Further stratified analyses revealed that the positive effects of soy isoflavone supplementation were observed only among women with lower initial baseline BMC (median or less). In conclusion, soy isoflavones have a mild, but significant, independent effect on the maintenance of hip BMC in postmenopausal women with low initial bone mass.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Community and Family Medicine, Chinese University of Hong Kong, Hong Kong.

    , , ,

    Source

    MeSH

    Asian Continental Ancestry Group
    Bone Density
    Double-Blind Method
    Female
    Humans
    Isoflavones
    Middle Aged
    Osteoporosis, Postmenopausal
    Patient Compliance
    Soybean Proteins

    Pub Type(s)

    Clinical Trial
    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    14557449

    Citation

    Chen, Yu-Ming, et al. "Soy Isoflavones Have a Favorable Effect On Bone Loss in Chinese Postmenopausal Women With Lower Bone Mass: a Double-blind, Randomized, Controlled Trial." The Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 10, 2003, pp. 4740-7.
    Chen YM, Ho SC, Lam SS, et al. Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. J Clin Endocrinol Metab. 2003;88(10):4740-7.
    Chen, Y. M., Ho, S. C., Lam, S. S., Ho, S. S., & Woo, J. L. (2003). Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. The Journal of Clinical Endocrinology and Metabolism, 88(10), pp. 4740-7.
    Chen YM, et al. Soy Isoflavones Have a Favorable Effect On Bone Loss in Chinese Postmenopausal Women With Lower Bone Mass: a Double-blind, Randomized, Controlled Trial. J Clin Endocrinol Metab. 2003;88(10):4740-7. PubMed PMID: 14557449.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. AU - Chen,Yu-Ming, AU - Ho,Suzanne C, AU - Lam,Silvia S H, AU - Ho,Susan S S, AU - Woo,Jean L F, PY - 2003/10/15/pubmed PY - 2003/11/13/medline PY - 2003/10/15/entrez SP - 4740 EP - 7 JF - The Journal of clinical endocrinology and metabolism JO - J. Clin. Endocrinol. Metab. VL - 88 IS - 10 N2 - Animal studies have shown that soy isoflavones have an effect in preventing estrogen-related bone loss, but few data are available in humans, especially in the Asian populations. This double-blind, placebo-controlled, randomized trial examines the effects of soy isoflavones on bone loss in postmenopausal Chinese women, aged 48-62 yr. Two hundred and three eligible subjects were randomly assigned to three treatment groups with daily doses of placebo (1 g starch; n = 67), mid-dose (0.5 g starch, 0.5 g soy extracts, and approximately 40 mg isoflavones; n = 68), and high dose (1.0 g soy extracts and approximately 80 mg isoflavones; n = 68). All were given 12.5 mmol (500 mg) calcium and 125 IU vitamin D(3). Bone mineral density (BMD) and bone mineral content (BMC) of the whole body, spine, and hip were measured using dual energy x-ray absorptiometry at baseline and 1 yr post treatment. Both univariate and multivariate analyses showed that women in the high dose group had mild, but statistically significantly, higher favorable change rate in BMC at the total hip and trochanter (P < 0.05) compared with the placebo and mid-dose groups, even after further adjustments for the potential confounding factors. Further stratified analyses revealed that the positive effects of soy isoflavone supplementation were observed only among women with lower initial baseline BMC (median or less). In conclusion, soy isoflavones have a mild, but significant, independent effect on the maintenance of hip BMC in postmenopausal women with low initial bone mass. SN - 0021-972X UR - https://www.unboundmedicine.com/medline/citation/14557449/Soy_isoflavones_have_a_favorable_effect_on_bone_loss_in_Chinese_postmenopausal_women_with_lower_bone_mass:_a_double_blind_randomized_controlled_trial_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2003-030290 DB - PRIME DP - Unbound Medicine ER -